Hutchmed licenses KRAS-EGFR antibody-conjugate therapy from GSK
Hutchmed (China) Limited announced an exclusive licensing agreement with GSK covering the KRAS-EGFR antibody conjugate cancer therapy, including HMPL-A830.
Hutchmed (China) Limited said on 03 September 2026 that it has entered into a licensing agreement with GSK for HMPL-A830, described as a first-in-class KRAS-EGFR antibody-targeted therapy conjugate ("ATTC"). The company said the exclusive licence covers HMPL-A830, which is expected to enter cli…